Evercore Initiates Coverage on Kailera Therapeutics (NASDAQ:KLRA)

Equities researchers at Evercore started coverage on shares of Kailera Therapeutics (NASDAQ:KLRA) in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The brokerage set an “outperform” rating on the stock.

A number of other research firms also recently commented on KLRA. Wall Street Zen raised shares of Kailera Therapeutics to a “hold” rating in a research note on Saturday, April 25th. Jefferies Financial Group assumed coverage on shares of Kailera Therapeutics in a report on Tuesday. They issued a “buy” rating and a $48.00 target price for the company. TD Cowen assumed coverage on shares of Kailera Therapeutics in a research report on Tuesday. They set a “buy” rating and a $57.00 price target for the company. Finally, William Blair assumed coverage on shares of Kailera Therapeutics in a research note on Tuesday. They set an “outperform” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $42.75.

Kailera Therapeutics Trading Down 5.3%

NASDAQ KLRA opened at $21.11 on Tuesday. Kailera Therapeutics has a twelve month low of $20.86 and a twelve month high of $28.23.

Insider Activity at Kailera Therapeutics

In related news, major shareholder Rtw Investments, Lp acquired 500,000 shares of the business’s stock in a transaction on Monday, April 20th. The shares were bought at an average cost of $16.00 per share, with a total value of $8,000,000.00. Following the completion of the transaction, the insider directly owned 10,776,820 shares of the company’s stock, valued at $172,429,120. This trade represents a 4.87% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Andrew T. Kaplan bought 8,398,438 shares of the stock in a transaction dated Monday, April 20th. The stock was bought at an average price of $16.00 per share, with a total value of $134,375,008.00. Following the purchase, the director owned 26,255,581 shares of the company’s stock, valued at approximately $420,089,296. This represents a 47.03% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders purchased 10,460,938 shares of company stock worth $167,375,008.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.